BioVie IncBIVI
Price$1.47

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$22.1MTTM through 30 Jun 2026
Free Cash Flow -$19MTTM through 30 Jun 2026

Margins

Current

Returns

-127.6%ROE
-113.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio10.48x
Net Debt-$13.1Mnet cash position
Cash & Equivalents$9M

Quality Metrics

Altman Z-Score-39.09
Piotroski F-Score1 / 9
Earnings-Beat Rate33.3%

Multi-Year Trend

Diluted EPS-$3.05TTM
'20'21'22'23'24'25'26
FY2026: $-3.05

Dividend

No dividend

Capital Allocation

R&D Spend$14M

Segment Performance

SegmentRevenueYoYOutlook
Biopharmaceutical Drug Development$0
View details

Topline data readouts for Parkinson's Phase 2b study expected in late July/early August 2026, and ADDRESS-LC Phase 2 study in late August/early September 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.